On June 12th, 2023 local time, Sanyou Biopharmaceuticals Co., Ltd. officially announced the launch of "Sanyou Super Trillion Common Light Chain Antibody Discovery Platform" (the "platform").

As one of the nine trillion antibody discovery platforms of Sanyou, the platform features a library capacity of up to 1.12E+12 CFU. For a single target, the platform can generate hundreds of lead antibodies with diverse sequences, which can be further designed into bispecific antibodies with good drug developability, providing a feasible solution for obtaining bispecific antibodies with structures similar to the natural monoclonal antibodies.

Bispecific antibodies are at the forefront of antibody R&D field. Compared with monoclonal antibodies, bispecific antibodies possess one additional antigen binding arm, which brings stronger specificity and better targeting. As of March of 2023, 436 bispecific antibody drug candidates have advanced to clinical trials worldwide, and 10 bispecific antibody drugs had been approved for marketing, with sales of more than 5 billion USD.

Following the customer-oriented concept, the platform provides two types of services, i.e., library screening and library integration, making it not only suitable for the R&D service of individual projects, but also for customers’ integration into their own platforms with the exclusively customized common light chain libraries.

It is believed that the launch of the platform will provide customers with great assistance in overcoming the difficulties in the R&D of bispecific antibody drugs, reducing the challenges in the development of bispecific antibody drugs, and greatly accelerating the R&D of bispecific antibodies.